Literature DB >> 7579397

Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis.

P A von dem Borne1, J C Meijers, B N Bouma.   

Abstract

Recently, an alternative pathway for factor XI activation has been described in which factor XI is activated by thrombin. Patients with a factor XI deficiency bleed mostly from tissues with high local fibrinolytic activity. Therefore, the role of thrombin-mediated factor XI activation in both fibrin formation and fibrinolysis was studied in a plasma system. Clotting was induced by the addition of tissue factor or thrombin to recalcified plasma in the presence or absence of tissue-type plasminogen activator, after which clot formation and lysis were measured using turbidimetry. Thrombin-mediated activation of factor XI was found to take place in plasma under physiologic conditions in the absence of a dextran sulfate-like cofactor. At high tissue factor concentrations, no effect of factor XI was seen on the rate of fibrin formation. Decreasing amounts of tissue factor resulted in a gradually increasing contribution of factor XI to the rate of fibrin formation. In addition, thrombin-mediated factor XI activation resulted in an inhibition of tissue-type plasminogen activator-induced lysis of the clot. This inhibition occurred even at tissue factor concentrations at which no effect of factor XI was observed on fibrin formation. Trace amounts of activated factor XI (1.25 pmol/L, representing 0.01% activation) were capable of completely inhibiting fibrinolysis in our system. The inhibitory effect was found to be mediated by thrombin that is additionally generated in a factor XI-dependent manner via the intrinsic pathway and is capable of protecting the clot against lysis. We also observed that formation of additional thrombin continued after the clot had been formed. We conclude that thrombin-mediated factor XI activation can take place in plasma. The presence of factor XI during coagulation results in the formation of additional thrombin within the clot capable of protecting this clot from fibrinolytic attack. The large amounts of thrombin that are formed by the intrinsic pathway via factor XI may play an important role in the procoagulant and thrombogenic state of clots and may therefore have important clinical and therapeutic implications.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7579397

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  48 in total

Review 1.  Hageman factor, platelets and polyphosphates: early history and recent connection.

Authors:  J Caen; Q Wu
Journal:  J Thromb Haemost       Date:  2010-04-30       Impact factor: 5.824

Review 2.  Disseminated intravascular coagulation: old disease, new hope.

Authors:  Cheng Hock Toh; Michael Dennis
Journal:  BMJ       Date:  2003-10-25

3.  Factor XI-deficient mice display reduced inflammation, coagulopathy, and bacterial growth during listeriosis.

Authors:  Deyan Luo; Frank M Szaba; Lawrence W Kummer; Lawrence L Johnson; Erik I Tucker; Andras Gruber; David Gailani; Stephen T Smiley
Journal:  Infect Immun       Date:  2011-10-17       Impact factor: 3.441

4.  Deficiency in thrombin-activatable fibrinolysis inhibitor (TAFI) protected mice from ferric chloride-induced vena cava thrombosis.

Authors:  Xinkang Wang; Patricia L Smith; Mei-Yin Hsu; Joseph A Tamasi; Eileen Bird; William A Schumacher
Journal:  J Thromb Thrombolysis       Date:  2007-02       Impact factor: 2.300

5.  Spatial propagation and localization of blood coagulation are regulated by intrinsic and protein C pathways, respectively.

Authors:  Mikhail A Panteleev; Mikhail V Ovanesov; Dmitrii A Kireev; Aleksei M Shibeko; Elena I Sinauridze; Natalya M Ananyeva; Andrey A Butylin; Evgueni L Saenko; Fazoil I Ataullakhanov
Journal:  Biophys J       Date:  2005-12-02       Impact factor: 4.033

6.  Solution structure of the A4 domain of factor XI sheds light on the mechanism of zymogen activation.

Authors:  Dharmaraj Samuel; Hong Cheng; Paul W Riley; Adrian A Canutescu; Chandrasekaran Nagaswami; John W Weisel; Zimei Bu; Peter N Walsh; Heinrich Roder
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-20       Impact factor: 11.205

Review 7.  Clot Structure and Implications for Bleeding and Thrombosis.

Authors:  Emily Mihalko; Ashley C Brown
Journal:  Semin Thromb Hemost       Date:  2019-10-15       Impact factor: 4.180

8.  Abnormal plasma clot structure and stability distinguish bleeding risk in patients with severe factor XI deficiency.

Authors:  M Zucker; U Seligsohn; O Salomon; A S Wolberg
Journal:  J Thromb Haemost       Date:  2014-06-19       Impact factor: 5.824

9.  Uneventful cesarean delivery with administration of factor XI concentrate in a patient with severe factor XI deficiency.

Authors:  Georgios Mavromatidis; Konstantinos Dinas; Dimitrios Delkos; Fotios Goutzioulis; Christos Vosnakis; Emmanouel Hatzipantelis; Vassilia Garipidou; David Rousso
Journal:  Int J Hematol       Date:  2007-10       Impact factor: 2.490

Review 10.  Sulfated Non-Saccharide Glycosaminoglycan Mimetics as Novel Drug Discovery Platform for Various Pathologies.

Authors:  Daniel K Afosah; Rami A Al-Horani
Journal:  Curr Med Chem       Date:  2020       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.